1. Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?

   • John W. Stevens

   Current Opinion 20 June 2018 Pages: 1135 - 1141

2. Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Rachid Rafia
   • Abdullah Pandor
   • Robert Cutting

   Review Article 28 March 2018 Pages: 1143 - 1151

3. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Angela Stainthorpe
   • Janette Greenhalgh
   • Daniel Palmer

   Review Article Open access 29 March 2018 Pages: 1153 - 1163

4. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review

   • Carlos E. Rodriguez-Martinez
   • Monica P. Sossa-Briceño
   • Jose A. Castro-Rodriguez

   Systematic Review 04 June 2018 Pages: 1165 - 1200

   

5. Costs of Invasive Meningococcal Disease: A Global Systematic Review

   • Bing Wang
   • Renee Santoreneos
   • Helen Marshall

   Systematic Review 09 June 2018 Pages: 1201 - 1222

   

6. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations

   • Luis Hernandez
   • Malinda O’Donnell
   • Maarten Postma

   Systematic Review 03 July 2018 Pages: 1223 - 1252

   

7. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis

   • Jesse Elliott
   • Bláthnaid McCoy
   • Doug Coyle

   Original Research Article 15 May 2018 Pages: 1253 - 1261

   

8. The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study

   • José Leal
   • Stefania Manetti
   • James Buchanan

   Original Research Article Open access 22 May 2018 Pages: 1263 - 1272

   

9. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

   • Mahdi Gharaibeh
   • Ali McBride
   • Ivo Abraham

   Original Research Article 09 June 2018 Pages: 1273 - 1284

   

10. Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany

    • Afschin Gandjour
    • Dennis A. Ostwald

    Original Research Article 27 July 2018 Pages: 1285 - 1296

    

11. Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial

    • Baptiste Leurent
    • Manuel Gomes
    • James Carpenter

    Letter to the Editor 10 August 2018 Pages: 1297 - 1297